Investigation of multiple immune-checkpoints in the context of the disease for personalized therapy selection


PD1 blockade trough monoclonal antibody-based therapy has revolutionized the immunotherapeutic approach against solid tumors, however only a small number of patients benefits from this treatment due to the lack of accurate methodology including immunohistochemistry to guide patient that could respond to this immune checkpoint inhibitor therapy. Understanding the tumor microenvironment (TME) complexity with a single biomarker is not accurate enough to predict the interaction of the drug in its site of action and, therefore, its effectiveness. Here, we present a strategy in which the TME is deeply investigated at the molecular level in order to guide more efficiently the patient toward single or combination therapy.

To read more…

Search news